KIT and melanoma: Whereas targeted therapy against c-KIT has been effective in treating gastrointestinal stromal tumors (GIST) [35], its inhibitory activity is far less impressive in c-KIT-mutant melanoma, and responses tend to be short lived, with a median time to progression of three months [33].